Lipocalin-2 increases fat oxidation in vitro and is correlated with energy expenditure in normal weight but not obese women

Obesity

Volumn 21, Issue 12, 2013, Pages

  Paton, Chad M ^a   Rogowski, Michael P ^a   Kozimor, Amanda L ^a   Stevenson, Jada L ^a   Chang, Hui ^a   Cooper, Jamie A ^a  

^a TEXAS TECH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; OLEIC ACID;

ADIPOCYTE; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOBESITY ACTIVITY; ARTICLE; BODY WEIGHT; CALORIMETRY; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE ASSOCIATION; DRUG ACTIVITY; DRUG EFFICACY; ENERGY EXPENDITURE; FATTY ACID OXIDATION; FEMALE; GENE EXPRESSION REGULATION; HUMAN; IN VITRO STUDY; METABOLIC REGULATION; MIDDLE AGED; MOUSE; NONHUMAN; OBESITY; POSTPRANDIAL STATE; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; UPREGULATION; YOUNG ADULT;

ANIMALIA; MUS;

3T3-L1 CELLS; ACUTE-PHASE PROTEINS; ADIPOCYTES; ADOLESCENT; ADULT; ANIMALS; BODY MASS INDEX; BODY WEIGHT; CALORIMETRY, INDIRECT; CROSS-OVER STUDIES; ENERGY METABOLISM; FATTY ACIDS; FATTY ACIDS, MONOUNSATURATED; FATTY ACIDS, UNSATURATED; FEMALE; GENE EXPRESSION REGULATION; HUMANS; LIPID METABOLISM; LIPOCALINS; MICE; MICE, INBRED C57BL; MIDDLE AGED; OBESITY; OLEIC ACID; OXIDATION-REDUCTION; POSTPRANDIAL PERIOD; PPAR GAMMA; PROTO-ONCOGENE PROTEINS; RECOMBINANT PROTEINS; SINGLE-BLIND METHOD; YOUNG ADULT;

EID: 84889664247     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1002/oby.20507     Document Type: Article

References (24)

1. Rabe K, Lehrke M, Parhofer KG, et al. Adipokines and insulin resistance. Mol Med 2008; 14: 741-751.
2. Yan QW, Yang Q, Mody N, et al. The adipokine lipocalin 2 is regulated by obesity and promotes insulin resistance. Diabetes 2007; 56: 2533-2540.
3. Flowers MT, Paton CM, O'Byrne SM, et al. Metabolic changes in skin caused by SCD1 deficiency: a focus on retinol metabolism. PLoS One 2011; 6: e19734.
4. Guo H, Jin D, Zhang Y, et al. Lipocalin 2 deficiency impairs thermogenesis and potentiates diet-induced insulin resistance in mice. Diabetes 2010; 59: 1376-1385.
5. Law IK, Xu A, Lam KS, et al. Lipocalin-2 deficiency attenuates insulin resistance associated with ageing and obesity. Diabetes 2010; 59: 872-882.
6. Jun LS, Siddall CP, Rosen ED,. A minor role for lipocalin 2 in high-fat diet-induced glucose intolerance. Am J Physiol Endocrinol Metab 2011; 301: E825-E835.
7. Auguet T, Quintero Y, Terra X, et al. Upregulation of lipocalin 2 in adipose tissues of severely obese women: positive relationship with proinflammatory cytokines. Obesity 2011; 19: 2295-2300.
8. Tan BK, Adya R, Shan X, et al. Ex vivo and in vivo regulation of lipocalin-2, a novel adipokine, by insulin. Diabetes Care 2009; 32: 129-131.
9. Kanaka-Gantenbein C, Margeli A, Pervanidou P, et al. Retinol-binding protein 4 and lipocalin-2 in childhood and adolescent obesity: when children are not just small adults. Clin Chem 2008; 54: 1176-1182.
10. Wang Y, Lam KSL, Kraegen EW, et al. Lipocalin-2 is an inflammatory marker closely associated with obesity, insulin resistance, and hyperglycemia in humans. Clin Chem 2007; 53: 34-41.
11. Liu X, Hamnvik OP, Petrou M, et al. Circulating lipocalin 2 is associated with body fat distribution at baseline but is not an independent predictor of insulin resistance: the prospective cyprus metabolism study. Eur J Endocrinol 2011; 165: 805-812.
12. Choi KM, Kim TN, Yoo HJ, et al. Effect of exercise training on A-FABP, lipocalin-2 and RBP4 levels in obese women. Clin Endocrinol 2009; 70: 569-574.
13. Lee YH, Lee SH, Jung ES, et al. Visceral adiposity and the severity of coronary artery disease in middle-aged subjects with normal waist circumference and its relation with lipocalin-2 and MCP-1. Atherosclerosis 2010; 213: 592-597.
14. Catalín V, Gomez-Ambrosi J, Rodriguez A, et al. Increased adipose tissue expression of lipocalin-2 in obesity is related to inflammation and matrix metalloproteinase-2 and metalloproteinase-9 activities in humans. J Mol Med 2009; 87: 803-813.
15. Folch J, Lees M, Stanley GHS,. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 1957; 226: 497-509.
16. Weir JB,. New methods for calculating metabolic rate with special reference to protein metabolism. J Physiol 1949; 109: 1-9.
17. Frayn KN,. Calculation of substrate oxidation rates in vivo from gaseous exchange. J Appl Physiol 1983; 55: 628-634.
18. Guo H, Zhang Y, Brockman DA, et al. Lipocalin 2 deficiency alters estradiol production and estrogen receptor signaling in female mice. Endocrinology 2012; 153: 1183-1193.
19. Jin D, Guo H, Bu SY, et al. Lipocalin 2 is a selective modulator of peroxisome proliferator-activated receptor-gamma activation and function in lipid homeostasis and energy expenditure. FASEB J 2011; 25: 754-764.
20. Randle PJ, Garland PB, Hales CN, et al. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963; 1: 785-789.
21. Auguet T, Quintero Y, Terra X, et al. Upregulation of lipocalin 2 in adipose tissues of severely obese women: positive relationship with proinflammatory cytokines. Obesity 2011; 19: 2295-2300.
22. Tan BK, Adya R, Shan X, et al. Ex vivo and in vivo regulation of lipocalin-2, a novel adipokine, by insulin. Diabetes Care 2009; 32: 129-131.
23. Liu X, Hamnvik OP, Petrou M, et al. Circulating lipocalin 2 is associated with body fat distribution at baseline but is not an independent predictor of insulin resistance: the prospective Cyprus Metabolism Study. Eur J Endocrinol 2011; 165: 805-812.
24. Wang Y, Lam KSL, Kraegen EW, et al. Lipocalin-2 is an inflammatory marker closely associated with obesity, insulin resistance, and hyperglycemia in humans. Clin Chem 2007; 53: 34-41.